Northwest Biotherapeutics NWBO Stock
Northwest Biotherapeutics Price Chart
Northwest Biotherapeutics NWBO Financial and Trading Overview
| Northwest Biotherapeutics stock price | 0.28 USD |
| Previous Close | 0.65 USD |
| Open | 0.65 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.65 - 0.68 USD |
| 52 Week Range | 0.45 - 1.27 USD |
| Volume | 1.2M USD |
| Avg. Volume | 1.74M USD |
| Market Cap | 706.51M USD |
| Beta (5Y Monthly) | -0.129225 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NWBO Valuation Measures
| Enterprise Value | 757.48M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 327.0876 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 350.687 |
| Enterprise Value/EBITDA | -11.413 |
Trading Information
Northwest Biotherapeutics Stock Price History
| Beta (5Y Monthly) | -0.129225 |
| 52-Week Change | -4.41% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.27 USD |
| 52 Week Low | 0.45 USD |
| 50-Day Moving Average | 0.59 USD |
| 200-Day Moving Average | 0.7 USD |
NWBO Share Statistics
| Avg. Volume (3 month) | 1.74M USD |
| Avg. Daily Volume (10-Days) | 2.08M USD |
| Shares Outstanding | 1.09B |
| Float | 1B |
| Short Ratio | 13.54 |
| % Held by Insiders | 11.18% |
| % Held by Institutions | 0.28% |
| Shares Short | 14.14M |
| Short % of Float | 15.08% |
| Short % of Shares Outstanding | 11.34% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:16 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3141.61% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -133.52% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 2.16M USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | 118.39% |
| Gross Profit (ttm) | -33828000 USD |
| EBITDA | -66372000 USD |
| Net Income Avi to Common (ttm) | -101865000 USD |
| Diluted EPS (ttm) | -0.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.19M USD |
| Total Cash Per Share (mrq) | 0.006 USD |
| Total Debt (mrq) | 31.36M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.212 |
| Book Value Per Share (mrq) | -0.052 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -51047000 USD |
| Levered Free Cash Flow (ttm) | -117794872 USD |
Profile of Northwest Biotherapeutics
| Country | United States |
| State | MD |
| City | Bethesda |
| Address | 4800 Montgomery Lane |
| ZIP | 20814 |
| Phone | 240 497 9024 |
| Website | https://www.nwbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Q&A For Northwest Biotherapeutics Stock
What is a current NWBO stock price?
Northwest Biotherapeutics NWBO stock price today per share is 0.28 USD.
How to purchase Northwest Biotherapeutics stock?
You can buy NWBO shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Northwest Biotherapeutics?
The stock symbol or ticker of Northwest Biotherapeutics is NWBO.
Which industry does the Northwest Biotherapeutics company belong to?
The Northwest Biotherapeutics industry is Biotechnology.
How many shares does Northwest Biotherapeutics have in circulation?
The max supply of Northwest Biotherapeutics shares is 1.39B.
What is Northwest Biotherapeutics Price to Earnings Ratio (PE Ratio)?
Northwest Biotherapeutics PE Ratio is now.
What was Northwest Biotherapeutics earnings per share over the trailing 12 months (TTM)?
Northwest Biotherapeutics EPS is -0.07 USD over the trailing 12 months.
Which sector does the Northwest Biotherapeutics company belong to?
The Northwest Biotherapeutics sector is Healthcare.
Northwest Biotherapeutics NWBO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite Total Return I XCMP | 21258.23 USD — |
-0.1
|
— — | 20967.6 USD — | 21382.13 USD — | — - | — — |
- {{ link.label }} {{link}}